Substituted acrylamides were used as templates that bridge P1 and P4 binding elements, resulting in a series of potent sub-nanomolar) and selective factor Xa inhibitors. In this template, cis-geometry of P1 and P4 ligands is highly preferred. SAR on the substituting groups, as well as on modification of P1 and P4 moieties is described. Compounds in this series show good in vivo efficacy in animal models. (C) 2002 Elsevier Science Ltd. All rights reserved.
INHIBITORS OF FACTOR Xa
申请人:COR THERAPEUTICS, INC.
公开号:EP1159264A2
公开(公告)日:2001-12-05
US6399627B1
申请人:——
公开号:US6399627B1
公开(公告)日:2002-06-04
[EN] INHIBITORS OF FACTOR Xa<br/>[FR] INHIBITEURS DU FACTEUR Xa
申请人:COR THERAPEUTICS INC
公开号:WO2000047554A2
公开(公告)日:2000-08-17
Novel compounds of formula in which A is a substituted or unsubstituted phenyl, naphthyl or monocyclic heterocyclic ring, D is a substituted or unsubstituted phenyl or aromatic six-membered heterocyclic ring, K is a substituted or unsubstituted phenyl, naphthyl or bicyclic heterocyclic ring, and the other variables are as defined in the claims, their salts and other derivatives and compositions related thereto having activity against mammalian Factor Xa are disclosed. The coumpounds are useful in vitro or in vivo for preventing or treating coagulation disorders.
Inhibitors of factor Xa
申请人:Cor Therapeutics, Inc.
公开号:US06399627B1
公开(公告)日:2002-06-04
Novel compounds, their salts and compositions related thereto having activity against mammalian factor Xa are disclosed. The compounds are useful in vitro or in vivo for preventing or treating coagulation disorders.